cetylpyridinium chloride anhydrous has been researched along with kiss1 protein, human in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doi, R; Fujii, N; Ito, T; Katagiri, F; Kawaguchi, Y; Kida, A; Koizumi, M; Masui, T; Nagai, K; Oishi, S; Tomita, K; Uemoto, S | 1 |
| Colombel, M; MacLean, DB; Matsui, H; Neuwirth, R; Suri, A | 1 |
1 trial(s) available for cetylpyridinium chloride anhydrous and kiss1 protein, human
| Article | Year |
|---|---|
Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Drugs, Investigational; Health; Humans; Kisspeptins; Luteinizing Hormone; Male; Middle Aged; Orchiectomy; Placebos; Prostatic Neoplasms; Testosterone | 2014 |
1 other study(ies) available for cetylpyridinium chloride anhydrous and kiss1 protein, human
| Article | Year |
|---|---|
Prognostic value of metastin expression in human pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Female; Health; Humans; Immunohistochemistry; Kisspeptins; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Prognosis; Receptors, G-Protein-Coupled; Receptors, Kisspeptin-1; Recurrence; Survival Rate; Tumor Suppressor Proteins | 2009 |